Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab vs placebo and tofacitinib in rheumatoid arthritis (ContRAst-3 China)
CTR20202431Phase 3Terminated
- Sponsor
- GSK
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of otilimab in rheumatoid arthritis (RA), sponsored by GSK. Started Dec 2020; status: terminated.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20202431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202431.